Ensign Peak Advisors
VIVO

Ensign Peak Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

Ensign Peak Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-16,540
Closed -$503K – 2379
2022
Q2 		$503K Hold
16,540
– – ﹤0.01% 1453
2022
Q1 		$429K Hold
16,540
– – ﹤0.01% 1615
2021
Q4 		$337K Sell
16,540
-17,560
-51% -$337K ﹤0.01% 1775
2021
Q3 		$656K Hold
34,100
– – ﹤0.01% 1565
2021
Q2 		$756K Hold
34,100
– – ﹤0.01% 1510
2021
Q1 		$895K Buy
34,100
+20,200
+145% +$480K ﹤0.01% 1458
2020
Q4 		$260K Buy
+13,900
New +$260K ﹤0.01% 1694

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ensign Peak Advisors's VIVO Position: Q3 2022 in Review

Ensign Peak Advisors sold out of Meridian Bioscience Inc (VIVO) in Q3 2022, closing a stake of 16,540 shares — an estimated $503K sold.

Ensign Peak Advisors first reported a position in VIVO in Q4 2020 and held it in 7 quarters. The position peaked at $895K in Q1 2021. 203 funds tracked by Wall St. Rank hold VIVO as of Q3 2022.

  • Ensign Peak Advisors reported no remaining Meridian Bioscience Inc position as of Q3 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 16,540 Meridian Bioscience Inc shares in Q3 2022, an estimated $503K.
  • Ensign Peak Advisors first reported a position in Meridian Bioscience Inc in Q4 2020 and held it in 7 quarters.
  • Ensign Peak Advisors's Meridian Bioscience Inc position peaked at $895K in Q1 2021.
  • 203 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2022.

Based on Ensign Peak Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.